A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation protects at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can vary from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by activating the mother’s immune system to generate defence proteins, which are then passed to the foetus through the placenta. This maternal immunity provides newborns with instant defence from the moment of birth, precisely when they are highly susceptible to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence indicating that a fortnight’s interval is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to have the vaccine at the recommended time, whilst noting that protection can still occur even if given later in the third trimester.
- Nearly 85 per cent coverage when immunised 4 weeks before birth
- Maternal antibodies passed through placenta safeguard newborns from day one
- Protection possible with two-week gap before premature birth
- Vaccination during the third trimester still offers meaningful protection for infants
Compelling evidence from recent research
The effectiveness of the pregnancy RSV vaccine has been confirmed through a thorough investigation undertaken in England, analysing data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that half-year window, providing comprehensive and reliable information of the vaccine’s real-world impact. The study’s findings have been validated by the UK Health Security Agency as showing strong protection for newborns during their earliest and most vulnerable period. The breadth of this investigation gives healthcare professionals and prospective parents with trust in the vaccine’s established performance across varied populations and settings.
The results reveal a compelling picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV during the study period, with the vast majority being infants whose mothers did not receive the vaccination. This stark contrast emphasises the vaccine’s critical role in protecting against serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a major public health success, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme launched in the UK in 2024.
Methodology and scope of study
The research examined birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection rates and hospitalisations. The sizeable sample and thorough nature of the data gathering ensured that findings were statistically robust and representative of the broader population, rather than isolated cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to determine the least amount of time between vaccination and birth for maximum protection, as well as to determine whether protection stayed significant with shorter intervals. The methodology captured actual clinical results rather than experimental conditions, providing tangible evidence of how the vaccine works when given across varied healthcare environments and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the hazards
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.
The infection triggers inflammation deep within the lungs and airways, making it dangerously difficult for infected babies to breathe and feed properly. Parents frequently observe their babies struggling visibly, their chests heaving as they try to pull enough air into their compromised lungs. Whilst most newborns get better with palliative treatment, a small but significant number die from RSV-related complications yearly, making vaccination as prevention a vital health service priority for protecting the youngest and most at-risk individuals in the population.
- RSV produces inflammation in lungs, leading to severe breathing difficulties in infants
- Approximately half of infants contract the infection during their first few months alive
- Symptoms span from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- More than 20,000 UK babies require serious hospital care for RSV annually
- Few babies succumb to RSV complications each year in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme commenced in 2024, health officials have stressed the value of pregnant women receiving their jab at the optimal time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing matters greatly for ensuring newborns benefit from the most robust immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery delivers nearly 85% protection, experts recommend women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to maximise the antibodies transferred to their babies via the placenta.
The guidance from health authorities remains clear: pregnant women should prioritise getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has reassured pregnant women that protection is still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those giving birth ahead of schedule. This flexible approach recognises the realities of pregnancy and childbirth whilst maintaining strong protection for at-risk infants during their most critical early months when RSV represents the highest danger of serious illness.
Regional variations in vaccination
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Certain regions have achieved greater immunisation rates among qualifying expectant mothers, whilst others continue working to boost understanding and availability of the jab. These geographical variations reflect variations in medical facilities, communication strategies, and community involvement initiatives, though the overall statistics shows consistently strong protection irrespective of geographical location.
- NHS trusts rolling out multiple messaging strategies to reach expectant mothers
- Inconsistencies across regions in vaccination coverage levels throughout England require targeted improvement
- Community health services adapting programmes to align with community needs and circumstances
Practical implications and parental perspectives
The vaccine’s remarkable effectiveness provides tangible benefits for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the rollout of this preventative solution, the 80% decrease in admissions means thousands of infants shielded from critical disease. Parents no more face the distressing scenario of seeing their babies struggle for breath or labour to feed, symptoms that mark serious RSV disease. The vaccine has markedly changed the landscape of neonatal respiratory health, offering expectant mothers a proactive tool to protect their most at-risk babies during those critical early months.
For families like that of Malachi, whose serious RSV infection caused severe brain damage, the vaccine’s introduction carries profound emotional significance. His mother’s promotion of the jab emphasises the life-altering consequences that vaccine-preventable disease can cause to young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story strikes a chord with parents now offered protection. The knowledge that such grave complications—hospital admission, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to pregnant women during their final trimester, changing what was once an predictable seasonal threat into a controllable health concern.